The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-arm, open-label, multi-center study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
I. W. Flinn
Research Funding - Novartis
S. Goldberg
Honoraria - Novartis
Research Funding - Novartis
R. L. Robles
No relevant relationships to disclose
D. Rizzieri
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
J. P. Radich
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
M. J. Mauro
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
S. Ericson
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
J. E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Deciphera; Novartis; Pfizer